BACKGROUND: Prostate cancer is the second leading cause of men cancer-related death. Cancer immunotherapy has been investigated as a treatment which might be instituted at the point of detection of androgen-independent metastatic disease. AIM: to investigate the expression and humoral response against NYESO-1 in patients with prostate cancer (PC) and to analyze the relationship between expression of NY-ESO-1 and clinicopathological features. METHODS: NY-ESO-1 mRNA in surgically resected PC and benign prostatic hyperplasia (BPH) were examined by reverse transcriptionpolymerase chain reaction. The antibody response to NY-ESO-1 was examined by enzyme-linked Elisa assay using recombinant NYESO-1 protein. RESULTS: NY-ESO-1 mRNA was detected in 9 of 23 (39%) PC patients. Antibodies against NY-ESO-1 protein were detected in 12 of 23 (52%) sera of PC patients and in 5 of 9 (55%) of NY-ESO-1 expressing tumors. However, no mRNA copy or NY-ESO-1 antibodies were detected in all BPH patients tested. CONCLUSION: The present study has demonstrated the expression of NY-ESO-1mRNA in prostate Cancer patients and NY-ESO-1 antibody production. Our data suggest that NY-ESO-1 could be used as a tumor marker and constitute a good candidate for vaccine-based immunotherapy for hormonal resistant prostate cancer patients.
BACKGROUND:Prostate cancer is the second leading cause of mencancer-related death. Cancer immunotherapy has been investigated as a treatment which might be instituted at the point of detection of androgen-independent metastatic disease. AIM: to investigate the expression and humoral response against NYESO-1 in patients with prostate cancer (PC) and to analyze the relationship between expression of NY-ESO-1 and clinicopathological features. METHODS:NY-ESO-1 mRNA in surgically resected PC and benign prostatic hyperplasia (BPH) were examined by reverse transcriptionpolymerase chain reaction. The antibody response to NY-ESO-1 was examined by enzyme-linked Elisa assay using recombinant NYESO-1 protein. RESULTS:NY-ESO-1 mRNA was detected in 9 of 23 (39%) PC patients. Antibodies against NY-ESO-1 protein were detected in 12 of 23 (52%) sera of PC patients and in 5 of 9 (55%) of NY-ESO-1 expressing tumors. However, no mRNA copy or NY-ESO-1 antibodies were detected in all BPH patients tested. CONCLUSION: The present study has demonstrated the expression of NY-ESO-1mRNA in prostate Cancerpatients and NY-ESO-1 antibody production. Our data suggest that NY-ESO-1 could be used as a tumor marker and constitute a good candidate for vaccine-based immunotherapy for hormonal resistant prostate cancerpatients.
Authors: Adeline N Boettcher; Ahmed Usman; Alicia Morgans; David J VanderWeele; Jeffrey Sosman; Jennifer D Wu Journal: Front Oncol Date: 2019-09-11 Impact factor: 6.244
Authors: William S Chen; Winston A Haynes; Rebecca Waitz; David Y Oh; John C Shon; Felix Y Feng; Kathy Kamath; Agustin Vega-Crespo; Raunak Shrestha; Minlu Zhang; Adam Foye; Ignacio Baselga Carretero; Ivan Perez Garcilazo; Meng Zhang; Shuang G Zhao; Martin Sjöström; David A Quigley; Jonathan Chou; Tomasz M Beer; Matthew Rettig; Martin Gleave; Christopher P Evans; Primo Lara; Kim N Chi; Robert E Reiter; Joshi J Alumkal; Alan Ashworth; Rahul Aggarwal; Eric J Small; Patrick S Daugherty; Antoni Ribas Journal: Clin Cancer Res Date: 2020-09-23 Impact factor: 12.531
Authors: S Fujiwara; H Wada; J Kawada; R Kawabata; T Takahashi; J Fujita; T Hirao; K Shibata; Y Makari; S Iijima; H Nishikawa; A A Jungbluth; Y Nakamura; Y Kurokawa; M Yamasaki; H Miyata; K Nakajima; S Takiguchi; E Nakayama; M Mori; Y Doki Journal: Br J Cancer Date: 2013-02-12 Impact factor: 7.640
Authors: Harm Westdorp; Annette E Sköld; Berit A Snijer; Sebastian Franik; Sasja F Mulder; Pierre P Major; Ronan Foley; Winald R Gerritsen; I Jolanda M de Vries Journal: Front Immunol Date: 2014-05-06 Impact factor: 7.561